ALBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Albireo Pharma's Enterprise Value is $745.07 Mil. Albireo Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-123.53 Mil. Therefore, Albireo Pharma's EV-to-EBIT ratio for today is -6.03.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Albireo Pharma's Enterprise Value is $745.07 Mil. Albireo Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-123.10 Mil. Therefore, Albireo Pharma's EV-to-EBITDA ratio for today is -6.05.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Albireo Pharma's Enterprise Value is $745.07 Mil. Albireo Pharma's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $57.39 Mil. Therefore, Albireo Pharma's EV-to-Revenue ratio for today is 12.98.
The historical data trend for Albireo Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albireo Pharma Annual Data | |||||||||||||||||||||
Trend | Sep12 | Sep13 | Sep14 | Sep15 | Sep16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Enterprise Value | Get a 7-Day Free Trial | 174.68 | 128.76 | 192.25 | 475.05 | 211.31 |
Albireo Pharma Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Enterprise Value | Get a 7-Day Free Trial | 348.71 | 211.31 | 375.71 | 218.49 | 178.13 |
For the Biotechnology subindustry, Albireo Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Albireo Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Albireo Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Albireo Pharma's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
Enterprise Value (A: Dec. 2021 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 449.417814 | + | 0 | + | 10.004 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0 | + | 0 | - | 248.107 |
= | 211.31 |
Albireo Pharma's Enterprise Value for the quarter that ended in Sep. 2022 is calculated as
Enterprise Value (Q: Sep. 2022 ) | |||||
= | Market Cap | + | Preferred Stock | + | Long-Term Debt & Capital Lease Obligation |
= | 400.610672 | + | 0 | + | 0 |
+ | Short-Term Debt & Capital Lease Obligation | + | Minority Interest | - | Cash, Cash Equivalents, Marketable Securities |
+ | 0 | + | 0 | - | 222.476 |
= | 178.13 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albireo Pharma (NAS:ALBO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Albireo Pharma's EV-to-EBIT for today is
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | 745.074 | / | -123.525 | |
= | -6.03 |
Albireo Pharma's current Enterprise Value is $745.07 Mil.
Albireo Pharma's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.53 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Albireo Pharma's EV-to-EBITDA for today is:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA(TTM) |
= | 745.074 | / | -123.096 | |
= | -6.05 |
Albireo Pharma's current Enterprise Value is $745.07 Mil.
Albireo Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.10 Mil.
3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.
Albireo Pharma's EV-to-Revenue for today is:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 745.074 | / | 57.391 | |
= | 12.98 |
Albireo Pharma's current Enterprise Value is $745.07 Mil.
Albireo Pharma's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $57.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Albireo Pharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Harford Simon N.r. | officer: CFO and Treasurer | AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Pamela Stephenson | officer: Chief Commercial Officer | C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
Martha J. Carter | officer: Chief Regulatory Officer | C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960 |
Jan Mattsson | officer: Chief Operating Officer | C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109 |
Cooper Ronald Harold Wilfred | director, officer: President and CEO | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Michelle Graham | officer: Chief Human Resources Officer | 10000 WEHRLE DRIVE, CLARENCE NY 14031 |
Jason Duncan | officer: General Counsel | C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
Paul Streck | officer: Chief Medical Officer | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Craig C. Hopkinson | director | 852 WINTER STREET, WALTHAM MA 02451 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Susan Alesina | director | C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109 |
Habib J Dable | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
Patrick Taylor Horn | officer: Chief Medical Officer | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By Value_Insider Value_Insider • 11-03-2022
By Stock market mentor Stock market mentor • 02-03-2023
By Stock market mentor Stock market mentor • 01-25-2023
By PRNewswire PRNewswire • 01-31-2023
By Value_Insider Value_Insider • 12-06-2022
By Value_Insider Value_Insider • 11-02-2022
By PRNewswire PRNewswire • 01-10-2023
By Business Wire Business Wire • 01-09-2023
By PRNewswire PRNewswire • 01-31-2023
By PRNewswire PRNewswire • 01-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.